ABSTRACT:
Background: A variety of medications, such as a-1 adrenergic antagonist doxazosin, can be used to treat benign prostatic hyperplasia. Majority of drug treatments have been given through oral route because of its convenience but it may produce many drawbacks includes high and frequent dosing and GIT complications. Hence, to overcome the drawbacks to improve bioavailability and prolonged drug release, present research aimed to develop a transdermal product for doxazosin mesylate. Methods: Using solvent casting method, different patches were formulated using various ratios of polymers such as HPMCK100 and PVP K30. Results: The prepared patches were evaluated for folding endurance, moisture content, percentage drug content, thickness, in vitro drug release studies, kinetics of the drug release, and FTIR studies respectively. Compared with PVP K30 at three different ratios, the lowest level of HPMCK100 shown around two folds increase in all the evaluated parameters. Conclusion: Transdermal patches of six were prepared successfully and the optimized batch PF4 was shown maximum drug release in 12 h and kinetics followed first order drug release and diffusion process. Based on the obtained results, penetration of doxazocin mesylate was improved across the skin and it concluded that as an effective dosage for transdermal delivery.